An Improved Peptide Manufacturing Platform for the Production of Etelcalcetide
Improved peptide manufacturing process of etelcalcetide, the active ingredient in, Parsabiv™— a drug for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease. This novel process reduces chemical solvent use by 71%, manufacturing operating time by 56%, and manufacturing costs by 76%. This could eliminate over 14,400 cubic meters of waste, including 750 cubic meters of aqueous waste, while increasing profits.